Correlation of the abundance of MDSCs, Tregs, PD-1, and PD-L1 with the efficacy of chemotherapy and prognosis in gastric cancer.

Laboratory medicine Pub Date : 2024-11-20 DOI:10.1093/labmed/lmae090

Na Li, Yun Li, Jing Li, Shimin Tang, Hongbo Gao, Yong Li

{"title":"Correlation of the abundance of MDSCs, Tregs, PD-1, and PD-L1 with the efficacy of chemotherapy and prognosis in gastric cancer.","authors":"Na Li, Yun Li, Jing Li, Shimin Tang, Hongbo Gao, Yong Li","doi":"10.1093/labmed/lmae090","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to investigate the relationship between tumor microenvironment markers (myeloid-derived suppressor cells [MDSCs], regulatory T cells [Tregs], programmed cell death 1 [PD-1], and programmed death ligand 1 [PD-L1]) and chemotherapy efficacy and prognosis in advanced gastric cancer, identifying potential monitoring indicators.Methods: Advanced gastric cancer patients' MDSC and Treg expression was measured by flow cytometry pre- and postchemotherapy; PD-1 and PD-L1 expression in cancer tissues was assessed by immunohistochemistry. Correlations with chemotherapy outcomes and prognosis were analyzed.Results: Postchemotherapy reductions in MDSC and Treg levels correlated with chemotherapy efficacy (P <.01). Negative PD-1 and PD-L1 expression in cancer tissues predicted better chemotherapy responses (P <.01). Patients with lower MDSC and Treg levels and negative PD-1 and PD-L1 had significantly longer median progression-free survival (PFS) and overall survival (OS) (P <.05).Conclusion: In advanced gastric cancer, reduced peripheral blood MDSC and Treg levels postchemotherapy and negative PD-1 and PD-L1 expression in tissues are associated with improved chemotherapy efficacy and are independent prognostic factors for PFS and OS.","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/labmed/lmae090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study was to investigate the relationship between tumor microenvironment markers (myeloid-derived suppressor cells [MDSCs], regulatory T cells [Tregs], programmed cell death 1 [PD-1], and programmed death ligand 1 [PD-L1]) and chemotherapy efficacy and prognosis in advanced gastric cancer, identifying potential monitoring indicators.

Methods: Advanced gastric cancer patients' MDSC and Treg expression was measured by flow cytometry pre- and postchemotherapy; PD-1 and PD-L1 expression in cancer tissues was assessed by immunohistochemistry. Correlations with chemotherapy outcomes and prognosis were analyzed.

Results: Postchemotherapy reductions in MDSC and Treg levels correlated with chemotherapy efficacy (P <.01). Negative PD-1 and PD-L1 expression in cancer tissues predicted better chemotherapy responses (P <.01). Patients with lower MDSC and Treg levels and negative PD-1 and PD-L1 had significantly longer median progression-free survival (PFS) and overall survival (OS) (P <.05).

Conclusion: In advanced gastric cancer, reduced peripheral blood MDSC and Treg levels postchemotherapy and negative PD-1 and PD-L1 expression in tissues are associated with improved chemotherapy efficacy and are independent prognostic factors for PFS and OS.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胃癌中 MDSCs、Tregs、PD-1 和 PD-L1 的数量与化疗疗效和预后的相关性。

研究目的本研究旨在探讨肿瘤微环境标志物（髓源抑制细胞[MDSCs]、调节性T细胞[Tregs]、程序性细胞死亡1[PD-1]和程序性死亡配体1[PD-L1]）与晚期胃癌化疗疗效和预后之间的关系，确定潜在的监测指标：方法：通过流式细胞术检测晚期胃癌患者化疗前后MDSC和Treg的表达；通过免疫组化评估癌组织中PD-1和PD-L1的表达。分析了化疗结果与预后的相关性：结果：化疗后MDSC和Treg水平的降低与化疗疗效相关（P 结论：化疗后MDSC和Treg水平的降低与化疗疗效相关：在晚期胃癌中，化疗后外周血 MDSC 和 Treg 水平的降低以及组织中 PD-1 和 PD-L1 的阴性表达与化疗疗效的改善相关，并且是 PFS 和 OS 的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Laboratory medicine

自引率

0.00%

发文量